1. Home
  2. ICCC vs NTHI Comparison

ICCC vs NTHI Comparison

Compare ICCC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$9.74

Market Cap

93.1M

Sector

Health Care

ML Signal

N/A

Logo NeOnc Technologies Holdings Inc.

NTHI

NeOnc Technologies Holdings Inc.

N/A

Current Price

$3.01

Market Cap

106.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICCC
NTHI
Founded
1982
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.1M
106.0M
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
ICCC
NTHI
Price
$9.74
$3.01
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
12.4K
★ 193.5K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.85
N/A
EPS
★ 0.41
N/A
Revenue
★ $26,493,169.00
$39,990.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.78
★ N/A
Revenue Growth
★ 51.64
N/A
52 Week Low
$4.52
$2.88
52 Week High
$12.10
$12.99

Technical Indicators

Market Signals
Indicator
ICCC
NTHI
Relative Strength Index (RSI) 49.44 39.18
Support Level $9.39 N/A
Resistance Level $10.16 $3.70
Average True Range (ATR) 0.26 0.32
MACD 0.01 -0.02
Stochastic Oscillator 67.27 13.93

Price Performance

Historical Comparison
ICCC
NTHI

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Share on Social Networks: